2008-03-06 16:52:41 -
www.illumina.com/ - Illumina, Inc. (NASDAQ:ILMN) today announced that the Company will webcast its presentations at the following three investment conferences:
Bear Stearns Annual London Healthcare Conference in London, England on March 13th. The live webcast is scheduled to begin at 7:00 a.m. ET and will feature an overview of the company by Christian Henry, Senior Vice
President and Chief Financial Officer, followed by a question and answer session.
Cowen Health Care Conference in Boston, Massachusetts on March 18th. The live webcast is scheduled to begin at 8:00 a.m. ET and will feature an overview of the company by Jay Flatley, President and Chief Executive Officer, followed by a question and answer session.
Lehman Brothers Healthcare Conference in Miami, Florida on March 20th. The live webcast is scheduled to begin at 9:30 a.m. ET and will feature an overview of the company by Jay Flatley, President and Chief Executive Officer, followed by a question and answer session
All live webcasts can be accessed under the "Corporate/Investor Information" tab of Illumina's web site at www.illumina.com.
About Illumina
Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of next-generation life-science tools and integrated systems for the large-scale analysis of genetic variation and biological function. Using our proprietary technologies, we provide a comprehensive line of products and services that currently serve the sequencing, genotyping, and gene expression markets, and we expect to enter the market for molecular diagnostics. Our customers include leading genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies. Our tools provide researchers around the world with the performance, throughput, cost effectiveness, and flexibility necessary to perform the billions of genetic tests needed to extract valuable medical information from advances in genomics and proteomics. We believe this information will enable researchers to correlate genetic variation and biological function, which will enhance drug discovery and clinical research, allow diseases to be detected earlier, and permit better choices of drugs for individual patients.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: this release may contain forward-looking statements that involve risks and uncertainties. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements Illumina's ability (i) to integrate effectively our recent acquisition of Solexa, Inc., (ii) to develop and commercialize further our BeadArray(TM), VeraCode(R) and Solexa(R) technologies and to deploy new gene expression and genotyping products and applications for our technology platforms, (iii) to manufacture robust micro arrays and Oligator(R) oligonucleotides, (iv) to integrate and scale our VeraCode technology, (v) to scale further oligo synthesis output and technology to satisfy market demand derived from our collaboration with Invitrogen, together with other factors detailed in our filings with the Securities and Exchange Commission including our recent filings on Forms 10-K and 10-Q or in information disclosed in public conference calls, the date and time of which are released beforehand. We disclaim any intent or obligation to update these forward-looking statements beyond the date of this release.
Illumina, Inc.
Media:
Maurissa Bornstein, Public Relations Manager
858-332-4055
mbornstein@illumina.com
or
Investors:
Peter J. Fromen, Sr. Director, Investor Relations
858-202-4507
pfromen@illumina.com 
